Related Experiment Video
Updated: Mar 26, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Nonsteroidal Anti-inflammatory-Organometallic Anticancer Compounds
Emilia Păunescu1, Sarah McArthur1, Mylène Soudani1
1Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
New ruthenium and osmium metal complexes linked to nonsteroidal anti-inflammatory drugs (NSAIDs) show enhanced anticancer activity. These novel compounds exhibit significant cytotoxicity against ovarian cancer cells, demonstrating potential as improved cancer therapeutics.
Area of Science:
- Organometallic Chemistry
- Medicinal Chemistry
- Cancer Biology
Background:
- Combining metal-based drugs with organic agents can yield superior anticancer properties.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin and diclofenac are widely used, but their anticancer potential is being explored.
- Ruthenium and osmium complexes offer unique properties for drug development.
Purpose of the Study:
- To synthesize and characterize novel organometallic ruthenium(II) and osmium(II) p-cymene complexes.
- To investigate the antiproliferative activity of these complexes against human ovarian cancer cells.
- To evaluate the selectivity of these novel compounds towards cancer cells versus normal cells.
Main Methods:
- Synthesis of Ru(II) and Os(II) p-cymene complexes featuring NSAIDs (indomethacin, diclofenac) via pyridine, phosphine, or bipyridine ligands.
- Assessment of antiproliferative effects using human ovarian cancer cell lines (A2780, A2780cisR) and HEK-293 cells.
- Evaluation of cytotoxicity and cancer cell selectivity of the synthesized complexes.
Main Results:
- Several synthesized Ru(II) and Os(II) complexes demonstrated significant cytotoxicity against ovarian cancer cells, including cisplatin-resistant lines.
- Some complexes exhibited considerably higher anticancer activity compared to the parent NSAIDs.
- The study observed notable selectivity of certain complexes towards cancer cells over nontumorigenic kidney cells.
Conclusions:
- Novel organometallic complexes of ruthenium and osmium, functionalized with NSAIDs, represent a promising class of anticancer agents.
- These compounds display potent antiproliferative effects and selectivity, warranting further investigation for cancer therapy.
- The strategic combination of metal centers and organic drugs offers a viable approach to developing more effective cancer treatments.
More Related Videos
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
09:00An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
Published on: March 18, 2015
Related Concept Videos
Properties of Organometallic Compounds
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Olefin Metathesis Polymerization: Acyclic Diene Metathesis (ADMET)
Similar to cross-metathesis, ADMET also involves the formation of metallacyclobutane intermediate by [2+2] cycloaddition of one of the double bonds of a terminal diene with...